EA201291225A1 - Улучшенные способы получения сквалена - Google Patents

Улучшенные способы получения сквалена

Info

Publication number
EA201291225A1
EA201291225A1 EA201291225A EA201291225A EA201291225A1 EA 201291225 A1 EA201291225 A1 EA 201291225A1 EA 201291225 A EA201291225 A EA 201291225A EA 201291225 A EA201291225 A EA 201291225A EA 201291225 A1 EA201291225 A1 EA 201291225A1
Authority
EA
Eurasian Patent Office
Prior art keywords
squal
squalene
improved ways
temperature
carried out
Prior art date
Application number
EA201291225A
Other languages
English (en)
Other versions
EA027142B1 (ru
Inventor
Мэниндер Хора
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44358794&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201291225(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201291225A1 publication Critical patent/EA201291225A1/ru
Publication of EA027142B1 publication Critical patent/EA027142B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C11/00—Aliphatic unsaturated hydrocarbons
    • C07C11/21—Alkatrienes; Alkatetraenes; Other alkapolyenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D3/00—Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping
    • B01D3/10—Vacuum distillation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D3/00—Distillation or related exchange processes in which liquids are contacted with gaseous media, e.g. stripping
    • B01D3/14—Fractional distillation or use of a fractionation or rectification column
    • B01D3/143—Fractional distillation or use of a fractionation or rectification column by two or more of a fractionation, separation or rectification step
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/10—Wash bottles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C7/00—Purification; Separation; Use of additives
    • C07C7/04—Purification; Separation; Use of additives by distillation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Улучшенный способ получения сквалена из скваленсодержащей композиции; причем указанный способ включает стадии (а) очищающей дистилляции, осуществляемой при температуре T; (b) денатурирующей дистилляции, осуществляемой при температуре Т; в котором стадии (а) и (b) можно осуществлять в любом порядке; Tи Тявляются достаточными, чтобы вызвать кипение сквалена; T>Tи Т≥200°С.
EA201291225A 2010-05-12 2011-05-12 Улучшенные способы получения сквалена EA027142B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39544810P 2010-05-12 2010-05-12
PCT/IB2011/001397 WO2011141819A1 (en) 2010-05-12 2011-05-12 Improved methods for preparing squalene

Publications (2)

Publication Number Publication Date
EA201291225A1 true EA201291225A1 (ru) 2013-06-28
EA027142B1 EA027142B1 (ru) 2017-06-30

Family

ID=44358794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291225A EA027142B1 (ru) 2010-05-12 2011-05-12 Улучшенные способы получения сквалена

Country Status (20)

Country Link
US (5) US9199897B2 (ru)
EP (4) EP2569267B2 (ru)
JP (2) JP5946188B2 (ru)
KR (1) KR101875894B1 (ru)
CN (2) CN105125488A (ru)
AU (1) AU2011251706B2 (ru)
BR (1) BR112012028711B1 (ru)
CA (1) CA2798924C (ru)
EA (1) EA027142B1 (ru)
ES (4) ES2597158T5 (ru)
IL (1) IL222855A (ru)
MX (1) MX352758B (ru)
NZ (1) NZ603918A (ru)
PL (4) PL3103784T3 (ru)
PT (3) PT3103784T (ru)
SG (2) SG10201503689TA (ru)
SI (1) SI2569267T1 (ru)
TR (1) TR201905021T4 (ru)
WO (1) WO2011141819A1 (ru)
ZA (1) ZA201208381B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2597158T5 (es) 2010-05-12 2020-03-26 Novartis Ag Procedimientos mejorados para preparar escualeno
HUE048398T2 (hu) * 2010-06-04 2020-07-28 Wyeth Llc Vakcinakészítmények
WO2013132041A2 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
EP3620172A1 (en) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
EP3052603B2 (en) * 2013-09-30 2023-08-09 AAK AB (publ) Enrichment of triterpene esters
EP3511020B1 (en) 2014-12-02 2021-01-20 Novartis AG Manufacture of surfactant-containing compositions
BR112020024702A2 (pt) * 2018-06-08 2021-03-23 Amyris, Inc. síntese de e,e-farnesol, acetato de farnesila e esqualeno a partir de farneseno via cloreto de farnesila
WO2023056089A1 (en) 2021-10-03 2023-04-06 Eisai R&D Management Co., Ltd. Immunological adjuvant formulations comprising tlr4 agonist e6020
WO2023250129A1 (en) * 2022-06-24 2023-12-28 Amyris, Inc. Compositions and methods for the purification of squalene

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060082A (en) 1976-08-16 1977-11-29 Mpl, Inc. Dual-ingredient medication dispenser
JPS57200142A (en) 1981-06-01 1982-12-08 Micron Kk Calculus removing tool
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
ES533744A0 (es) * 1984-06-27 1985-05-01 Bendiberica Sa Mecanismo de direccion asistida compacto
JPH0348427A (ja) 1989-04-04 1991-03-01 Matsushita Electric Ind Co Ltd バイポーラ半導体装置とその製造方法
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0614756Y2 (ja) 1991-06-26 1994-04-20 株式会社アルテ 組み立て式の２室式容器兼用注射器
JPH06116171A (ja) * 1992-10-06 1994-04-26 Nippon Fine Chem Co Ltd 天然スクワレンの精製方法
JP3484227B2 (ja) * 1994-05-20 2004-01-06 日清オイリオ株式会社 油脂からのスクワラン精製方法
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
WO1998001174A1 (fr) 1996-07-05 1998-01-15 Debiotech S.A. Seringue a chambre double permettant le melange de deux produits avant leur injection
US6090598A (en) * 1997-01-30 2000-07-18 Fuji Oil Company, Limited Enzymatic process for interesterification of fats and oils using distillation
GB9716578D0 (en) 1997-08-05 1997-10-08 Brf International Lipid removal
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
WO1999017820A1 (en) 1997-10-03 1999-04-15 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
US6165481A (en) * 1997-12-25 2000-12-26 Nippon Petrochemicals Company, Inc. Highly pure squalane, raw material for pharmaceuticals and cosmetics prepared by using the same and method for producing the same
DE19835749C1 (de) 1998-08-07 2000-02-03 Dieter Perthes Fertig-Spritze für nicht-stabile Arzneimittel
JP4282804B2 (ja) † 1998-12-24 2009-06-24 新日本石油株式会社 アジュバント組成物
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
MY142319A (en) * 2002-08-20 2010-11-15 Malaysian Palm Oil Board Mpob Extraction of palm vitamin e, phytosterols and squalene from palm oil
US20070092525A1 (en) * 2005-02-07 2007-04-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
ATE414715T1 (de) * 2003-09-04 2008-12-15 Biomay Ag Hypoallergene polypeptide basierend auf aus fisch gewonnenem parvalbumin
US7208627B2 (en) * 2003-12-18 2007-04-24 Nippon Shokubai Co., Ltd Alkylborazine compound and production method for the same
KR101153898B1 (ko) 2004-03-23 2012-06-18 니프로 가부시키가이샤 프리필드 시린지
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
ATE513561T1 (de) * 2005-11-04 2011-07-15 Novartis Vaccines & Diagnostic Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien
SI1951299T1 (sl) * 2005-11-04 2012-04-30 Novartis Vaccines & Diagnostic Cepiva proti influenci, ki vkljuäśujejo kombinacije adjuvantov iz delcev in imunopotenciatorjev
AU2006310163B2 (en) * 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CN100376519C (zh) 2006-02-23 2008-03-26 华南农业大学 一种制备角鲨烯的方法
ES2397714T3 (es) 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vacuna que comprende un adyuvante de emulsión de aceite en agua
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
ES2308924B1 (es) 2007-05-18 2009-11-02 Pradomudo Investigacion Y Desarrollo, S.L(Titular El 50%) Procedimiento de obtencion de escualeno.
FR2933403B1 (fr) * 2008-07-07 2010-08-27 Sophim Procede d'extration de squalene, de stereols et de vitamine e contenus dans des condensats de raffinage physique et/ou dans des distillats de desodorisation d'huiles vegetales
AU2009286426B2 (en) 2008-08-28 2013-08-22 Novartis Ag Production of squalene from hyper-producing yeasts
JP5642712B2 (ja) † 2009-02-10 2014-12-17 ノバルティス アーゲー 少ない量のスクアレンを含むインフルエンザワクチン
CN101597204B (zh) 2009-07-09 2013-03-13 天津大学 以橄榄油为原料提取高纯度角鲨烯的方法
CN101697204B (zh) 2009-10-23 2013-02-20 北京派瑞根科技开发有限公司 电子签章
EA025622B1 (ru) 2009-12-03 2017-01-30 Новартис Аг Способ получения содержащей сквален эмульсии масла
CA2782511C (en) 2009-12-03 2013-11-12 Novartis Ag Circulation of components during homogenization of emulsions
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
ES2597158T5 (es) * 2010-05-12 2020-03-26 Novartis Ag Procedimientos mejorados para preparar escualeno
CN101830770B (zh) 2010-06-02 2013-06-05 天津大学 从植物油脱臭馏出物中提取角鲨烯的方法
JP6116171B2 (ja) 2012-09-24 2017-04-19 株式会社ダスキン 左右開閉型払拭体保持具、払拭体及び清掃用具

Also Published As

Publication number Publication date
TR201905021T4 (tr) 2019-05-21
IL222855A (en) 2015-11-30
EP2569267A1 (en) 2013-03-20
ZA201208381B (en) 2014-04-30
BR112012028711A2 (pt) 2017-03-21
JP2015157858A (ja) 2015-09-03
ES2817446T3 (es) 2021-04-07
PL2569267T5 (pl) 2017-10-31
CN102892734B (zh) 2015-07-22
PL2569267T3 (pl) 2014-05-30
EP2569267B2 (en) 2017-03-22
PL2620423T3 (pl) 2017-09-29
EP3489211A1 (en) 2019-05-29
ES2717266T3 (es) 2019-06-20
US11077186B2 (en) 2021-08-03
ES2453316T5 (es) 2017-07-18
PT3489211T (pt) 2020-09-22
ES2597158T5 (es) 2020-03-26
CA2798924A1 (en) 2011-11-17
PT3103784T (pt) 2019-05-20
EP2569267B1 (en) 2013-12-25
EP2620423A1 (en) 2013-07-31
US9867877B2 (en) 2018-01-16
EP3103784B1 (en) 2019-02-06
EP2620423B1 (en) 2016-07-20
CN105125488A (zh) 2015-12-09
BR112012028711B1 (pt) 2020-12-01
US9545440B2 (en) 2017-01-17
MX352758B (es) 2017-12-07
US9199897B2 (en) 2015-12-01
SG10201503689TA (en) 2015-06-29
EP2620423B2 (en) 2019-07-31
PL2620423T5 (pl) 2019-12-31
EP3103784A1 (en) 2016-12-14
WO2011141819A1 (en) 2011-11-17
JP2013530941A (ja) 2013-08-01
US20170072053A1 (en) 2017-03-16
AU2011251706B2 (en) 2015-10-22
SG185419A1 (en) 2012-12-28
MX2012013027A (es) 2012-12-17
CA2798924C (en) 2014-05-06
EP3489211B1 (en) 2020-07-15
KR101875894B1 (ko) 2018-08-02
SI2569267T1 (sl) 2014-03-31
US10517947B2 (en) 2019-12-31
PL3103784T3 (pl) 2019-07-31
IL222855A0 (en) 2012-12-31
NZ603918A (en) 2015-04-24
PT2620423T (pt) 2016-09-23
AU2011251706A1 (en) 2012-12-20
EA027142B1 (ru) 2017-06-30
US20180169225A1 (en) 2018-06-21
US20160051670A1 (en) 2016-02-25
ES2597158T3 (es) 2017-01-16
ES2453316T3 (es) 2014-04-07
US20130209510A1 (en) 2013-08-15
CN102892734A (zh) 2013-01-23
JP5946188B2 (ja) 2016-07-05
KR20130103668A (ko) 2013-09-24
PL3489211T3 (pl) 2020-12-14
US20200061187A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
EA201291225A1 (ru) Улучшенные способы получения сквалена
EA201270616A1 (ru) Ингибиторы вируса гепатита с
EA201692036A3 (ru) Способ обработки лигноцеллюлозных материалов электронным излучением
EA201390190A1 (ru) Ингибиторы вируса гепатита с
UA111827C2 (uk) Спосіб отримання інгенол-3-ангелату
WO2011036564A3 (en) Hyperblebbing shigella strains
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201390538A1 (ru) Противовирусные соединения
TR201803560T4 (tr) Bitkiden türetilen proteinlerin hazırlanma metotları.
EA201490886A1 (ru) Переработка биомассы
MD20140035A2 (ru) Способ лечения вирусного гепатита С
EA201270423A1 (ru) Ингибиторы протеазы hcv
EA201270115A1 (ru) Биологические способы получения адипиновой кислоты
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA201290880A1 (ru) Новые соединения - ингибиторы фермента
TR201903336T4 (tr) Fermantasyonda gelişmiş karbon yakalama.
EA201071058A1 (ru) Получение леналидомида
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
MX2013001237A (es) Compuestos inhibidores del virus de la hepatitis c.
EA201370078A1 (ru) Ингибиторы вируса гепатита с
EA201390130A1 (ru) Способ получения противовирусных соединений
MX2013014002A (es) Inhibidores del virus de la hepatitis c.
EA201590698A1 (ru) Жидкофазные способы получения макроциклических депсипептидов и новые промежуточные соединения
BR112012010760A2 (pt) caldo de fermentação inseticida a partir de actinomicetos
EA201300440A1 (ru) Способ получения (3s,3s') 4,4'-дисульфандиилбис(3-аминобутан-1-сульфокислоты)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM